143 related articles for article (PubMed ID: 19056675)
41. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
42. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
[TBL] [Abstract][Full Text] [Related]
43. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Cai S; Xu Y; Cooper RJ; Ferkowicz MJ; Hartwell JR; Pollok KE; Kelley MR
Cancer Res; 2005 Apr; 65(8):3319-27. PubMed ID: 15833865
[TBL] [Abstract][Full Text] [Related]
44. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Wickström M; Dyberg C; Milosevic J; Einvik C; Calero R; Sveinbjörnsson B; Sandén E; Darabi A; Siesjö P; Kool M; Kogner P; Baryawno N; Johnsen JI
Nat Commun; 2015 Nov; 6():8904. PubMed ID: 26603103
[TBL] [Abstract][Full Text] [Related]
45. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
46. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
[TBL] [Abstract][Full Text] [Related]
47. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Rahman MA; Gras Navarro A; Brekke J; Engelsen A; Bindesbøll C; Sarowar S; Bahador M; Bifulco E; Goplen D; Waha A; Lie SA; Gjertsen BT; Selheim F; Enger PØ; Simonsen A; Chekenya M
Br J Cancer; 2019 Oct; 121(7):545-555. PubMed ID: 31413318
[TBL] [Abstract][Full Text] [Related]
48. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
Jiang G; Li LT; Xin Y; Zhang L; Liu YQ; Zheng JN
Curr Med Chem; 2012; 19(23):3886-92. PubMed ID: 22788764
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide.
Khusnutdinov RR; Boichuk SV
Bull Exp Biol Med; 2017 Jun; 163(2):260-262. PubMed ID: 28726196
[TBL] [Abstract][Full Text] [Related]
50. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
[TBL] [Abstract][Full Text] [Related]
51. MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1.
Huang Y; Rachid Z; Jean-Claude BJ
Mol Cancer Res; 2011 Mar; 9(3):320-31. PubMed ID: 21263032
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death.
Kaina B; Mühlhausen U; Piee-Staffa A; Christmann M; Garcia Boy R; Rösch F; Schirrmacher R
J Pharmacol Exp Ther; 2004 Nov; 311(2):585-93. PubMed ID: 15254145
[TBL] [Abstract][Full Text] [Related]
53. Dual repair modulation reverses Temozolomide resistance in vitro.
Barvaux VA; Ranson M; Brown R; McElhinney RS; McMurry TB; Margison GP
Mol Cancer Ther; 2004 Feb; 3(2):123-7. PubMed ID: 14985452
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
55. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
56. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents.
Glassner BJ; Weeda G; Allan JM; Broekhof JL; Carls NH; Donker I; Engelward BP; Hampson RJ; Hersmus R; Hickman MJ; Roth RB; Warren HB; Wu MM; Hoeijmakers JH; Samson LD
Mutagenesis; 1999 May; 14(3):339-47. PubMed ID: 10375003
[TBL] [Abstract][Full Text] [Related]
57. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
[TBL] [Abstract][Full Text] [Related]
58. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models.
Kato Y; Okollie B; Raman V; Vesuna F; Zhao M; Baker SD; Bhujwalla ZM; Artemov D
Cancer Biol Ther; 2007 Jun; 6(6):891-7. PubMed ID: 17582214
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
60. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Middleton MR; Lunn JM; Morris C; Rustin G; Wedge SR; Brampton MH; Lind MJ; Lee SM; Newell DR; Bleehen NM; Newlands ES; Calvert AH; Margison GP; Thatcher N
Br J Cancer; 1998 Nov; 78(9):1199-202. PubMed ID: 9820180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
